With biosimilar threat under control (for now), Roche savors demand for its new drugs
Roche $RHBBY unveiled a cheerful update on its performance in the first nine months of this year, with demand for its newer drugs — primarily in …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
